Skip to main content

Young Drug Users: a Vulnerable Population and an Underutilized Resource in HIV/HCV Prevention

Abstract

Purpose of Review

The social networks of people who inject drugs (PWID) have long been studied to understand disease transmission dynamics and social influences on risky practices. We illustrate how PWID can be active agents promoting HIV, HCV, and overdose prevention.

Recent Findings

We assessed drug users’ connections and interactions with others at risk for HIV/HCV in three cities: New York City (NYC), USA (n = 539); Pereira, Colombia (n = 50); and St. Petersburg, Russia (n = 49). In all three cities, the majority of participants’ network members were of a similar age as themselves, yet connections across age groups were also present. In NYC, knowing any opioid user(s) older than 29 was associated with testing HCV-positive. In NYC and St. Petersburg, a large proportion of PWID engaged in intravention activities to support safer injection and overdose prevention; in Pereira, PWID injected, had sex, and interacted with other key groups at risk.

Summary

People who use drugs can be active players in HIV/HCV and overdose risk- reduction; their networks provide them with ample opportunities to disseminate harm reduction knowledge, strategies, and norms to others at risk. Local communities could augment prevention programming by empowering drug users to be allies in the fight against HIV and facilitating their pre-existing health-protective actions.

This is a preview of subscription content, access via your institution.

References

  1. Degenhardt L, Peacock A, Colledge S, Leung J, Grebely J, Vickeran P. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review. Lancet Glob Health. 2017;5:e1192–207.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Merz F. United Nations Office on Drugs and Crime. World Drug Report 2017. https://www.unodc.org/wdr2017/index.html. Accessed 2 April 2018.

  3. World Health Organization. WHO, UNODC, UNAIDS technical guide for countries to set targets for universal access to HIV prevention, treatment and care for injecting drug users. 2012. http://apps.who.int/iris/bitstream/handle/10665/77969/9789241504379_eng.pdf;jsessionid=1ABEDB253458AEBFA58D90ED7212F250?sequence=1. Accessed 4 April 2018.

  4. Mathers BM, Degenhardt L, Ali H, Wiessing L, Hickman M, Mattick RP. HIV prevention, treatment, and care services for people who inject drugs: a systematic review of global, regional, and national coverage. Lancet. 2010;375:1014–28.

    Article  PubMed  Google Scholar 

  5. Degenhardt L, Mathers B, Vickerman P, Rhodes T, Latkin C, Hickman M. Prevention of HIV infection for people who inject drugs: why individual, structural, and combination approaches are needed. Lancet. 2010;376:285–301.

    Article  PubMed  Google Scholar 

  6. Des Jarlais DC, Hagan H, Friedman SR, Friedmann P, Goldberg D, Frischer M. Maintaining low HIV seroprevalence in populations of injecting drug users. JAMA. 1995;274:1226–31.

    Article  PubMed  CAS  Google Scholar 

  7. Wilson DP, Donald B, Shattock AJ, Wilson D, Fraser-Hurt N. The cost-effectiveness of harm reduction. Int J Drug Policy. 2015;26:S5–S11.

    Article  PubMed  Google Scholar 

  8. Jones CM, Christensen A, Gladden RM. Increases in prescription opioid injection abuse among treatment admissions in the United States, 2004–2013. Drug Alcohol Depend. 2017;176:89–95.

    Article  PubMed  Google Scholar 

  9. Liang TJ, Ward JW. Hepatitis C in injection-drug users—a hidden danger of the opioid epidemic. N Engl J Med. 2018;378:1169–71.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Zibbell JE, Iqbal K, Patel RC, Suryaprasad A, Sanders KJ, Moore-Moravian. Increases in hepatitis C virus infection related to injection drug use among persons aged≤ 30 years-Kentucky, Tennessee, Virginia, and West Virginia, 2006-2012. MMWR. 2015;64:453–8.

    PubMed  Google Scholar 

  11. Ly KN, Hughes EM, Jiles RB, Holmberg SD. Rising mortality associated with hepatitis C virus in the United States, 2003–2013. Clin Infect Dis. 2016;62:1287–8.

    Article  PubMed  Google Scholar 

  12. Campbell CA, Canary L, Smith N, Teshale E, Blythe Ryerson A, Ward JW. State HCV incidence and policies related to HCV preventive and treatment services for persons who inject drugs—United States, 2015–2016. Am J Transplant. 2017;17(7):1945–8.

    Article  PubMed  CAS  Google Scholar 

  13. Curtis R, Friedman SR, Neaigus A, Jose B, Goldstein M, Ildefonso G. Street-level drug markets: network structure and HIV risk. Soc Networks. 1995;17(3–4):229–49.

    Article  Google Scholar 

  14. Friedman SR, Neaigus A, Jose B, Curtis R, Goldstein M, Ildefonso G. Sociometric risk networks and risk for HIV infection. Am J Public Health. 1997;87(8):1289–96.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  15. Klovdahl AS, Potterat JJ, Woodhouse DE, Muth JB, Muth SQ, Darrow WW. Social networks and infectious disease: the Colorado Springs study. Soc Sci Med. 1994;38(1):79–88.

    Article  PubMed  CAS  Google Scholar 

  16. Suh T, Mandell W, Latkin C, Kim J. Social network characteristics and injecting HIV-risk behaviors among street injection drug users. Drug Alcohol Depend. 1997;47(2):137–43.

    Article  PubMed  CAS  Google Scholar 

  17. Weeks MR, Clair S, Borgatti SP, Radda K, Schensul JJ. Social networks of drug users in high-risk sites: finding the connections. AIDS Behav. 2002;6(2):193–206.

    Article  Google Scholar 

  18. Bouchard M, Hashimi S, Tsai K, Lampkin H, Jozaghi E. Back to the core: a network approach to bolster harm reduction among persons who inject drugs. Int J Drug Policy. 2018;51:95–104.

    Article  PubMed  Google Scholar 

  19. Latkin CA, Sherman S, Knowlton A. HIV prevention among drug users: outcome of a network-oriented peer outreach intervention. Health Psychol. 2003;22:332–9.

    Article  PubMed  Google Scholar 

  20. Medley A, Kennedy C, O'Reilly K, Sweat M. Effectiveness of peer education interventions for HIV prevention in developing countries: a systematic review and meta-analysis. AIDS Educ Prev. 2009;21:181–206.

    Article  PubMed  PubMed Central  Google Scholar 

  21. McCabe SE, Cranford JA, West BT. Trends in prescription drug abuse and dependence, co-occurrence with other substance use disorders, and treatment utilization: results from two national surveys. Addict Behav. 2008;33:1297–305.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Paulozzi LJ, Budnitz DS, Xi Y. Increasing deaths from opioid analgesics in the United States. Pharmacoepidemiol Drug Saf. 2006;15:618–27.

    Article  PubMed  Google Scholar 

  23. Rudd RA, Aleshire N, Zibbell JE, Matthew Gladden R. Increases in drug and opioid overdose deaths—United States, 2000–2014. Am J Transplant. 2016;16:1323–7.

    Article  Google Scholar 

  24. Cicero TJ, Ellis MS, Surratt HL, Kurtz SP. The changing face of heroin use in the United States: a retrospective analysis of the past 50 years. JAMA psychiatry. 2014;71:821–6.

    Article  PubMed  Google Scholar 

  25. Compton WM, Jones CM, Baldwin GT. Relationship between nonmedical prescription-opioid use and heroin use. N Engl J Med. 2016;374:154–63.

    Article  PubMed  CAS  Google Scholar 

  26. Jones CM. Heroin use and heroin use risk behaviors among nonmedical users of prescription opioid pain relievers–United States, 2002–2004 and 2008–2010. Drug Alcohol Depend. 2013;132:95–100.

    Article  PubMed  Google Scholar 

  27. Tempalski B, Pouget ER, Cleland CM, Brady JE, Cooper HL, Hall HI. Trends in the population prevalence of people who inject drugs in US metropolitan areas 1992–2007. PLoS One. 2013;8:e64789.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  28. Suryaprasad AG, White JZ, Xu F, Eichler BA, Hamilton J, Patel A. Emerging epidemic of hepatitis C virus infections among young nonurban persons who inject drugs in the United States, 2006–2012. Clin Infect Dis. 2014;59:1411–9.

    Article  PubMed  CAS  Google Scholar 

  29. Friedman SR, Maslow C, Bolyard M, Sandoval M, Mateu-Gelabert P, Neaigus A. Urging others to be healthy: “Intravention” by injection drug users as a community prevention goal. AIDS Educ Prev. 2004;16:250–63.

    Article  PubMed  Google Scholar 

  30. European Centre for Disease Prev Control Regional Office for Europe-WHO. 2016. https://ecdc.europa.eu/sites/portal/files/media/en/publications/Publications/HIV-AIDS-surveillance-Europe-2015.pdf. Accessed 29 March 2018.

  31. UNAIDS. The Gap Report. 2014. http://files.unaids.org/en/media/unaids/contentassets/documents/unaidspublication/2014/UNAIDS_Gap_report_en.pdf. Accessed 16 March 2018.

  32. Sarang A, Rhodes T, Sheon N, Page K. Policing drug users in Russia: risk, fear, and structural violence. Subst Use Misuse. 2010;45:813–64.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Lunze K, Raj A, Cheng DM, Quinn EK, Lunze FI, Liebschutz JM. Sexual violence from police and HIV risk behaviours among HIV-positive women who inject drugs in St. Petersburg, Russia—a mixed methods study. J Int AIDS Soc. 2016;19(4Suppl3):20877.

    PubMed  PubMed Central  Google Scholar 

  34. Clark F. World Report: Gaps remain in Russia’s response to HIV/AIDS. Lancet. 2016;388:857–8.

    Article  PubMed  Google Scholar 

  35. Ciccarone D. Heroin in brown, black and white: structural factors and medical consequences in the US heroin market. Int J Drug Policy. 2009;20:277–82.

    Article  PubMed  Google Scholar 

  36. Ministerio de Justicia y del Derecho, Observatorio de Drogas de Colombia. La Heroína en Colombia, Producción, uso e impacto en la salud pública - Análisis de la evidencia y recomendaciones de política. 2015. http://fileserver.idpc.net/library/CO03132015la_heroina_en_colombia_produccion_impacto_salud.pdf. Accessed 1 March 2018.

  37. Hacker MA, Malta M, Enriquez M, Bastos FI. Human immunodeficiency virus, AIDS, and drug consumption in South America and the Caribbean: epidemiological evidence and initiatives to curb the epidemic. Rev Panam Salud Publica. 2005;18:303–13.

    Article  PubMed  Google Scholar 

  38. Miguez MJ, Page B, Baum MK. Illegal drug use and HIV-1 infection in Colombia. Lancet. 1997;350:1635.

    Article  PubMed  CAS  Google Scholar 

  39. Mateu-Gelabert P, Harris S, Berbesi D, Segura Cardona ÁM, Montoya Vélez LP, Mejía Motta IE. Heroin use and injection risk behaviors in Colombia: implications for HIV/AIDS prevention. Subst Use Misuse. 2016;51:230–40.

    Article  PubMed  PubMed Central  Google Scholar 

  40. Castaño Pérez GA, Calderón Vallejo GA. Patterns of heroin use in a sample of consumers in Medellín-Colombia. Rev Bras Epidemiol. 2012;15:504–22.

    Article  PubMed  Google Scholar 

  41. García PJ, Bayer A, Cárcamo CP. The changing face of HIV in Latin America and the Caribbean. Curr HIV/AIDS Rep. 2014;11:146–57.

    Article  PubMed  PubMed Central  Google Scholar 

  42. Observatorio de Drogas del Eje Cafetero. Situación del consumo de drogas en Risaralda. Sistema único de indicadores sobre consumo de sustancias psicoactivas. 2010. http://www.odc.gov.co/Portals/1/Docs/SUISPA/SUISPA-Risaralda2010.pdf. Accessed 12 April 2018.

  43. Corporación ATS. Proyecto CAMBIE: Programa Integral Para Personas Que Se Inyectan Drogas. 2018. http://proyectocambie.com/cambie/#. Accessed 8 April 2018.

  44. Siegel JE, Weinstein MC, Fineberg HV. Bleach programs for preventing AIDS among iv drug users: modeling the impact of HIV prevalence. Am J Public Health. 1991;81:1273–9.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  45. Rhodes T. Risk environments and drug harms: a social science for harm reduction approach. Int J Drug Policy. 2009;20:193–201.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

This study was supported by US National Institutes of Health (NIH)/National Institute on Drug Abuse (NIDA) grants R01DA035146, R01DA041501, P30DA011041, and T32DA007233.

The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute on Drug Abuse or the National Institutes of Health.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Pedro Mateu-Gelabert.

Ethics declarations

Conflict of Interest

P. Meylakhs’ and A. Meylakhs’ effort on this paper was supported by the project Fostering Public Health and Quality of Life: Developing and Improving Current Methodology funded by the National Research University Higher School of Economics, St. Petersburg, Russia (2018).

P. Mateu-Gelabert, H. Guarino, K. Quinn, P. Meylakhs, S. Campos, A. Meylakhs, D. Berbesi, D. Toro-Tobón, E. Goodbody, D.C. Ompad, and S. R. Friedman declare that they have no competing interests.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on The Global Epidemic

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Mateu-Gelabert, P., Guarino, H., Quinn, K. et al. Young Drug Users: a Vulnerable Population and an Underutilized Resource in HIV/HCV Prevention. Curr HIV/AIDS Rep 15, 324–335 (2018). https://doi.org/10.1007/s11904-018-0406-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11904-018-0406-z

Keywords

  • People who inject drugs
  • HIV/HCV prevention
  • Young drug users
  • Opioid use